Table 1

Performance of the GenoType® MTBDRplus assay depending on the concentration of AFB in sputum specimens (N = 168)

Sputum AFB grading

OR

Previous anti-TB treatment

Unreadable GenoType® MTBDRplus patterns

(N = 14)

Unusual (double) GenoType® MTBDRplus patterns

(N = 39)


1 – 9 AFB/100 fields (n = 2)

1 (50.0%)

0


1+ (n = 64)

11 (17.2%)

21 (32.8%)


2+ (n = 60)

2 (3.3%)

12 (20.0%)


3+ (n = 42)

0

6 (14.3%)


New cases (N = 79)

7 (8.9%)

17 (21.5%)


Previously treated cases (N = 89)

7 (7.9%)

22 (24.7%)


Nikolayevskyy et al. BMC Clinical Pathology 2009 9:2   doi:10.1186/1472-6890-9-2

Open Data